Literature DB >> 20489063

Role of PET/CT in ovarian cancer.

Priyanka Prakash1, Carmel G Cronin, Michael A Blake.   

Abstract

OBJECTIVE: The purpose of this article is to review the role of FDG PET/CT in ovarian cancer, which is the leading cause of death among gynecologic cancers.
CONCLUSION: FDG PET/CT can significantly modify the assessment of the extent of primary and recurrent ovarian cancer and, hence, often alters patient management substantially. FDG PET/CT has thus become a critical tool for the preoperative evaluation of women with primary ovarian cancer and for postoperative follow-up assessment for evidence of recurrence in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20489063     DOI: 10.2214/AJR.09.3843

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  17 in total

1.  F-18 FDG PET/CT findings of metastatic ovarian tumors from gastrointestinal tract origin.

Authors:  Hye Lim Park; Ie Ryung Yoo; Joo Hyun O; Eun Ji Han; Sung Hoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-03       Impact factor: 4.553

Review 2.  Background, current role, and potential applications of radiogenomics.

Authors:  Katja Pinker; Fuki Shitano; Evis Sala; Richard K Do; Robert J Young; Andreas G Wibmer; Hedvig Hricak; Elizabeth J Sutton; Elizabeth A Morris
Journal:  J Magn Reson Imaging       Date:  2017-11-02       Impact factor: 4.813

3.  Value of (18)F-FDG PET/CT in the Detection of Ovarian Malignancy.

Authors:  Taegyu Park; Sinae Lee; Soyeon Park; Eunsub Lee; Kisoo Pahk; Seunghong Rhee; Jaehyuk Cho; Chulhan Kim; Jae Seon Eo; Jae Gol Choe; Sungeun Kim
Journal:  Nucl Med Mol Imaging       Date:  2014-10-28

4.  [Gynecological tumors of the true pelvis: Radiological diagnosis for pelvic tumors made simple].

Authors:  M Meissnitzer; T Meissnitzer; R Forstner
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

Review 5.  Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.

Authors:  Edward L Trimble; Michael J Birrer; William J Hoskins; Christian Marth; Ray Petryshyn; Michael Quinn; Gillian M Thomas; Henry C Kitchener; Carol Aghajanian; David S Alberts; Deborah Armstrong; Jubilee Brown; Robert L Coleman; Nicoletta Colombo; Elizabeth Eisenhauer; Michael Friedlander; Keiichi Fujiwara; Sally Hunsberger; Stan Kaye; Jonathan A Ledermann; Susanna Lee; Katherine Look; Robert Mannel; Iain A McNeish; Lori Minasian; Amit Oza; Jim Paul; Andres Poveda; Eric Pujade-Lauraine; Mason Schoenfeldt; Ann Marie Swart; Vivian von Gruenigen; Lari Wenzel
Journal:  Int J Gynecol Cancer       Date:  2010-10       Impact factor: 3.437

6.  A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.

Authors:  Carlotta Defferrari; Sara Campora; Mauro D'Amico; Arnoldo Piccardo; Ennio Biscaldi; Daniela Rosselli; Ambra Pasa; Matteo Puntoni; Alberto Gozza; Alessandra Gennari; Silvia Zanardi; Rita Lionetto; Michela Bandelloni; Andrea Decensi
Journal:  J Ovarian Res       Date:  2012-06-25       Impact factor: 4.234

7.  Role of multidetector computed tomography (MDCT) in patients with ovarian masses.

Authors:  Fatima Mubarak; Muhammad Shahbaz Alam; Waseem Akhtar; Saima Hafeez; Noureen Nizamuddin
Journal:  Int J Womens Health       Date:  2011-04-05

8.  Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.

Authors:  Christiaan Schiepers; Magnus Dahlbom
Journal:  Eur Radiol       Date:  2010-12-21       Impact factor: 5.315

9.  Preoperative [F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer.

Authors:  Hyun Hoon Chung; Hyun Woo Kwon; Keon Wook Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2012-01-09       Impact factor: 4.401

10.  Biologically-targeted detection of primary and micro-metastatic ovarian cancer.

Authors:  Tracy W Liu; Jocelyn M Stewart; Thomas D Macdonald; Juan Chen; Blaise Clarke; Jiyun Shi; Brian C Wilson; Benjamin G Neel; Gang Zheng
Journal:  Theranostics       Date:  2013-05-25       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.